Molecular Partners Ag (MOLN) EBITDA Margin (2020 - 2024)

Molecular Partners Ag (MOLN) has reported EBITDA Margin for 5 consecutive years, with 1226.15% the latest figure, recorded in Q4 2024.

• On a quarterly basis, EBITDA Margin rose 209451.0% year-over-year to 1226.15% in Q4 2024; TTM through Jun 2026 was 1274.57%, a 221634.0% decrease from a year earlier, with the FY2024 full-year figure at 1224.0%, up 209226.0% from the prior year.
• EBITDA Margin was 1226.15% for Q4 2024 at Molecular Partners Ag, up from 2142.29% in the prior quarter.
• Over five years, EBITDA Margin peaked at 5360.78% in Q3 2020 and troughed at 3827.23% in Q2 2023.
• A 5-year average of 429.65% and a median of 600.34% in 2022 frame the typical range for EBITDA Margin.
• Across the five-year window, EBITDA Margin slumped 572412 bps in 2021 and soared 279718 bps in 2024, its largest moves.
• Over 5 years, EBITDA Margin stood at 625.14% in 2020, then decreased by 4 bps to 650.22% in 2021, then jumped by 109 bps to 61.5% in 2022, then tumbled by 1512 bps to 868.37% in 2023, then jumped by 241 bps to 1226.15% in 2024.
• The last three EBITDA Margin figures came in at 1226.15% (Q4 2024), 2142.29% (Q3 2024), and 1030.05% (Q2 2024), per Business Quant data.